Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:51:49.945Z.
Calculation as of: 2026-10-06T15:51:49.945Z.
Quote observation: 2026-10-06T15:50:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 443dbef5a4958c6c8665db428659f78ed614b233762584452a295f0fd6fa7086
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Indaptus Therapeutics, Inc.
Market Cap
$283.42M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$283.92M
EV/Sales Ratio
N/A
TTM Avg
5.51x
3Y Avg
58.44x
5Y Avg
51.98x
Market Cap
$288.87M
EV/Sales Ratio
9.89x
TTM Avg
250.43x
3Y Avg
190.32x
5Y Avg
110.72x
Market Cap
$290.91M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$290.74M
EV/Sales Ratio
0.58x
TTM Avg
2.42x
3Y Avg
2.68x
5Y Avg
2.39x
Market Cap
$280.60M
EV/Sales Ratio
1.02x
TTM Avg
0.84x
3Y Avg
0.87x
5Y Avg
1.56x
Market Cap
$279.16M
EV/Sales Ratio
49.67x
TTM Avg
36.37x
3Y Avg
26.31x
5Y Avg
30.77x
Market Cap
$276.08M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$297.62M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | $283.42M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.92M | N/A | 5.51x | 58.44x | 51.98x |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.87M | 9.89x | 250.43x | 190.32x | 110.72x |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $290.91M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $290.74M | 0.58x | 2.42x | 2.68x | 2.39x |
| Aurora Cannabis Inc. (ACB)vs › | $280.60M | 1.02x | 0.84x | 0.87x | 1.56x |
| Fate Therapeutics, Inc. (FATE)vs › | $279.16M | 49.67x | 36.37x | 26.31x | 30.77x |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $276.08M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $297.62M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $269.13M | 64.91x | 74.23x | 31.36x | 21.18x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
